[Federal Register Volume 62, Number 14 (Wednesday, January 22, 1997)]
[Page 3299]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 97-1534]



Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.


    The inventions listed below are owned by agencies of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for U.S. companies and may also be available for licensing.

ADDRESS: Licensing information and copies of the U.S. patent 
applications listed below may be obtained by contacting the indicated 
licensing specialist at the Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A 
signed Confidential Disclosure Agreement will be required to receive 
copies of the patent applications.

2,2'-Bipyridyl, a Ferrous Chelator, Prevents Vasospasm in a Primate 
Model of Subarachnoid Hemorrhage

LL Horky (NINDS)

Serial No. 08/672,060 filed 26 Jun 96

Licensing Contact: Stephen Finley, Ph.D., 301/496-7735 ext 215

    Subarachnoid hemorrhage (SAH) occurs in 28,000 people per year in 
North America. Symptomatic vasospasm occurs in the majority of 
individuals suffering SAH and is the most common cause of morbidity and 
mortality in patients reaching neurological care. Specifically, 
vasospasm causes cerebral ischemia or stroke, and the prevention of 
vasospasm could prevent stroke and death as well as allow physicians 
more freedom in scheduling surgery when the operative risks are lower.
    Intravenous administration of 2,2'-bipyridyl successfully prevented 
vasospasm in a reliable primate model of subarachnoid hemorrhage. 
Bipyridyl may provide a safe, cost-effective and reliable therapy for 
vasospasm in the clinical setting. Additional ferrous chelates, which 
may also prove effective, are also embodied in the invention. 
(portfolio: Central Nervous System--Therapeutics, neurological, stroke)

Interleukin-4 Stimulated T-Lymphocyte Cell Death for the Treatment 
of Autoimmune Diseases, Allergic Disorders and Graft Rejection

MJ Lenardo, SA Boehme, J Critchfield (NIAID)

Serial No. 08/348,286 filed 30 Nov 94

Licensing Contact: Jaconda Wagner, J.D., 301/496-7735 ext 284

    The discovery that interleukin-4 (IL-4) predisposes T lymphocytes 
to programmed cell death (apoptosis) allows for a novel method of 
therapeutic intervention in diseases caused by the action of IL-4-
responsive T cells. Specifically, the therapy induces the death of a 
subpopulation of T lymphocytes that are capable of causing disease. 
Current therapies may cause general death or suppression of immune 
responses involving T-cells, severely comprising a patient's immune 
system. This treatment affects only the subset of T cells that react 
with a specified antigen, thereby leaving a patients immune system 
uncompromised. This invention is useful in treating allergies and HIV 
complications. Both fields are available for licensing (portfolio: 
Internal Medicine--Therapeutics, anti-inflammatory)

Interleukin-2 Stimulated T-Lymphocyte Cell Death for the Treatment 
of Autoimmune Diseases, Allergic Disorders and Graft Rejection

MJ Lenardo (NIAID)

Serial No. 08/482,724 filed 07 Jun 95

Licensing Contact: Jaconda Wagner, J.D., 301/496-7735 ext 284

    T-Cell apoptosis induced by administration of IL-2 and antigen 
offers an important new treatment for allergic disorders, which are due 
to the effects of antigen-activated T-cells. Antigen-activated T-cells 
cause the release of harmful lymphokines and the production of 
immunoglobulin E by B cells. Presently available methods for treating 
allergies have limitations because they are nonspecific in their action 
and have side effects and limited efficacy. IL-2 and antigen stimulates 
the programmed death of only antigen-specific T-cells while leaving the 
rest of the patient's T-cells and other immune cells intact. This 
invention is also useful in treating HIV. Both fields of use, allergies 
and HIV, are available for licensing. (portfolio: Internal Medicine--
Therapeutics, anti-inflammatory)

    Dated: January 13, 1997.
Barbara M. McGarey,
Deputy Director, Office of Technology Transfer.
[FR Doc. 97-1534 Filed 1-21-97; 8:45 am]